Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HORIZON I: Cediranib vs Bevacizumab in mCRC
NCT00278889Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Jan 2006
- Primary completion
- Nov 2007
- Modality
- Small Molecules
- Countries
- 9
01
Overview
Phase 2, randomised trial of cediranib in metastatic colorectal cancer (mCRC) (2 arms), sponsored by AstraZeneca. Primary endpoint: Progression Free Survival. Started Jan 2006; status: completed.
02
Drugs
cediranib
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT00278889.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00278889.